Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB013739 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Treatment A - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 5 mg QD and Metformin |
| Treatment B - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 15 mg QD and Metformin |
| Treatment C - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 50 mg QD and Metformin |
| Treatment D - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 100 mg QD and Metformin |
| Treatment E - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 200 mg QD and Metformin |
| Treatment F - Placebo | PLACEBO_COMPARATOR | Matching placebo |
| INCB013739 | EXPERIMENTAL | - |
| Matching Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| INCB013739 | DRUG | INCB013739 5 mg QD tablet |
| Placebo comparator matching INCB013739 | DRUG | Orally once daily tablet |
| Metformin | DRUG | - |
| Placebo | DRUG | Matching placebo of 100 mg BID |
Inclusion Criteria: * Established diagnosis of Type 2 Diabetes * Stable dose of metformin for more than 8 weeks Exclusion Criteria: * Subjects with Addison's disease or Cushing's Syndrome * Type 1 diabetes mellitus or secondary forms of diabetes * Subjects with uncontrolled thyroid disease * Hist...
INCB013739 is an investigational small molecule being developed for Type 2 Diabetes Mellitus. It has been studied in Phase 2 clinical trials for glycemic control in Type 2 diabetic patients, including in combination with metformin, and for its effect on insulin sensitivity in obese Type 2 diabetic subjects.
INCB013739 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. The company has conducted Phase 2 clinical trials of this investigational drug in the metabolic therapeutic area.
INCB013739 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, one with 302 participants and another with 24 participants, both in patients with Type 2 Diabetes.
INCB013739 has been studied in two completed Phase 2 clinical trials. NCT00478322 examined its effect on insulin sensitivity in obese Type 2 diabetic subjects with 24 participants. NCT00698230 evaluated its safety and efficacy plus metformin compared to metformin alone on glycemic control in 302 Type 2 diabetics.
No alternative names for INCB013739 have been identified. It is known only by its code name INCB013739 in clinical trial records. The drug is an investigational small molecule developed by Incyte Corporation for the treatment of Type 2 Diabetes Mellitus.